GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

Migration, Crosslink

📖

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-gabrf

📖 Wiki Page

gene1496 wordssynced 2026-04-02

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">gabrf</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRF</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq28</td>
</tr>
<tr>
<td class="label">GRCh38 Coordinates</td>
<td>chrX:151,326,150-151,403,792</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>7915</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000130714</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P18505</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>458 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~53 kDa</td>
</tr>
<tr>
<td class="label">EC50 for GABA</td>
<td>~10-20 μM</td>
</tr>
<tr>
<td class="label">Channel conductance</td>
<td>~30 pS</td>
</tr>
<tr>
<td class="label">Deactivation kinetics</td>
<td>Slow</td>
</tr>
<tr>
<td class="label">Benzodiazepine sensitivity</td>
<td>High</td>
</tr>
<tr>
<td class="label">Zinc inhibition</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Olfactory bulb</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Amygdala</td>
<td>Moderate</td>

...

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">gabrf</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GABRF</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq28</td>
</tr>
<tr>
<td class="label">GRCh38 Coordinates</td>
<td>chrX:151,326,150-151,403,792</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>7915</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000130714</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P18505</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>458 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~53 kDa</td>
</tr>
<tr>
<td class="label">EC50 for GABA</td>
<td>~10-20 μM</td>
</tr>
<tr>
<td class="label">Channel conductance</td>
<td>~30 pS</td>
</tr>
<tr>
<td class="label">Deactivation kinetics</td>
<td>Slow</td>
</tr>
<tr>
<td class="label">Benzodiazepine sensitivity</td>
<td>High</td>
</tr>
<tr>
<td class="label">Zinc inhibition</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Olfactory bulb</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Amygdala</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Cerebral cortex</td>
<td>Very low</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Very low</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Classic Receptors</td>
</tr>
<tr>
<td class="label">Diazepam</td>
<td>Potent agonist</td>
</tr>
<tr>
<td class="label">Zolpidem</td>
<td>Selective agonist</td>
</tr>
<tr>
<td class="label"> loreclezole</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Etomidate</td>
<td>Potent agonist</td>
</tr>
<tr>
<td class="label">Pentobarbital</td>
<td>Potent agonist</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">R252Q</td>
<td>Reduced function</td>
</tr>
<tr>
<td class="label">P331L</td>
<td>Altered gating</td>
</tr>
<tr>
<td class="label">G257S</td>
<td>Normal function</td>
</tr>
<tr>
<td class="label">Promoter variants</td>
<td>Altered expression</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

GABRF encodes the theta (θ) subunit of the GABA-A receptor, a member of the Cys-loop ligand-gated ion channel superfamily. While most GABA-A receptors contain α, β, and γ subunits, the theta subunit represents a rare and pharmacologically distinct isoform primarily expressed in specific brain regions. The theta subunit assembles with α3 and β3 subunits to form GABA-A receptors with unique gating properties and pharmacological profiles that differ substantially from the more common α1β2γ2 or α2βγ2 receptor configurations[@whittaker2010].

The GABRF gene is located on the X chromosome (Xq28) at position 151,326,150-151,403,792 (GRCh38), spanning approximately 77.6 kb of genomic DNA. The gene consists of 9 exons encoding a protein of 458 amino acids with a molecular weight of approximately 53 kDa. Unlike other GABA-A receptor subunits, GABRF shows highly restricted expression patterns, being expressed at detectable levels in only a few brain regions, making it a challenging target for study but also a potentially selective therapeutic target[@browne2015].

This review summarizes current knowledge about GABRF structure, function, expression patterns, and its potential involvement in neurological and neurodegenerative diseases.

Gene and Protein Structure

Genomic Organization

Protein Domain Architecture

The GABRF protein shares the characteristic structure of Cys-loop receptor subunits:

N-terminal extracellular domain (1-217 aa): Contains the characteristic Cys-loop motif (Cys-X-X-X-X-X-Cys) essential for ligand binding and allosteric modulation

Transmembrane domains (218-458 aa): Four α-helical transmembrane segments (TM1-4) that form the channel pore

Loop 2 domain: Large extracellular loop between TM2 and TM3 involved in channel gating

Intracellular loop: Between TM3 and TM4, contains sites for phosphorylation and trafficking signals

Distinct Structural Features

The theta subunit possesses several unique structural features compared to other GABA-A receptor subunits:

Extended intracellular loop: Contains multiple phosphorylation sites and trafficking motifs
Alternative N-terminal: The extracellular domain shows sequence variations affecting benzodiazepine binding
TM2-TM3 linker: Contains unique residues influencing gating kinetics

Receptor Assembly and Stoichiometry

Native Receptor Composition

Theta subunit-containing GABA-A receptors typically assemble as:

Primary configuration: α3β3θ (the most common native format)
Alternative configurations: α3θ, α4β3θ, or α5β3θ (less common)

The unique stoichiometry dramatically alters receptor properties:

Regional Expression Patterns

GABRF exhibits highly restricted expression in the human brain[@sur2018]:

Physiological Functions

Synaptic Inhibition

Theta-containing GABA-A receptors contribute to synaptic inhibition in several ways:

Phasic inhibition: Mediates fast synaptic inhibition at recurrent inhibitory synapses

Tonic inhibition: Generates persistent background conductance in specific neuronal populations

Temporal processing: Faster deactivation kinetics may contribute to precise temporal coding

Memory and Cognition

Emerging evidence suggests a role for theta-containing receptors in cognitive processes[@lakhani2019]:

Hippocampal theta rhythms: The restricted expression in CA3 suggests involvement in pattern separation
Memory consolidation: Theta subunit expression is modulated during memory consolidation
Spatial navigation: The olfactory bulb expression correlates with odor discrimination learning

Neuroendocrine Regulation

The hypothalamic expression of GABRF suggests involvement in:

Stress response regulation
Sleep-wake cycle control
Homeostatic function modulation

Role in Neurological Disorders

Alzheimer's Disease

GABAergic signaling is profoundly altered in Alzheimer's disease[@petrou2020]. The theta subunit shows unique changes:

Expression Alterations:

Reduced GABRF mRNA in hippocampus of AD patients
Altered subunit composition in cortical circuits
Correlation with cognitive decline severity

Therapeutic Implications[@zhang2021]:

Theta-containing receptors show enhanced sensitivity to certain allosteric modulators
Selective targeting may provide benefits without sedation
Zinc modulation offers another potential avenue

Parkinson's Disease

GABAergic dysfunction is a hallmark of Parkinson's disease[@olson2020]:

Basal ganglia alterations:

Enhanced GABRF expression in striatum
Altered receptor stoichiometry in substantia nigra
Contributes to motor circuitry dysfunction

Therapeutic relevance:

GABAergic modulation improves motor symptoms
Theta subunit targeting may provide subtype-selective effects

Epilepsy

Genetic variants in GABRF have been linked to epilepsy susceptibility[@hanlon2019]:

Pathogenic mechanisms:

Loss-of-function mutations reduce inhibitory tone
Altered channel gating increases neuronal excitability
Network hyperexcitability and seizure generation

Clinical correlations:

X-linked inheritance pattern
Variable expressivity based on X-chromosome inactivation
Potential as a biomarker for therapy response

Therapeutic Implications

Drug Development Targets

Theta-containing GABA-A receptors represent a promising target for subtype-selective modulation[@robello2013]:

Current approaches:

Allosteric modulators: Compounds that selectively enhance theta-containing receptors

Subunit-selective agonists: Development of drugs targeting the θ-containing receptors

Novel binding sites: Exploiting unique structural features for drug design

Challenges and Opportunities

Challenges:

Limited expression complicates drug targeting
Lack of selective pharmacological tools
Species differences in subunit distribution

Opportunities:

Reduced side effect profile due to restricted expression
Potential for cognitive enhancement without sedation
Disease-modifying potential through circuit normalization

Comparative Pharmacology

The theta subunit confers unique pharmacological properties[@maurer2017]:

Aging and Neurodegeneration

GABRF expression and function change during normal aging[@friedman2022]:

Expression decline: Reduced GABRF mRNA in aged brain
Functional consequences: Impaired inhibitory plasticity
Cognitive impact: Contributes to age-related memory decline

Neurodegenerative Vulnerability

Selective neuronal vulnerability in GABAergic disorders involves theta-containing receptors[@yang2021]:

Vulnerable neurons: Those with high theta expression show specific susceptibility
Mechanisms: Altered calcium homeostasis, oxidative stress
Therapeutic windows: Opportunities for targeted intervention

Interventional Strategies

GABAergic approaches to cognitive decline[@koh2022]:

Receptor modulators: Enhancing theta-containing receptor function
Gene therapy: Restoring GABRF expression
Combination approaches: GABAergic plus cholinergic enhancement

Genetic Variants and Polymorphisms

Disease-Associated Variants

Population Genetics

Minor allele frequencies: Generally rare variants
Ethnic variation: Some population-specific alleles
Evolutionary conservation: Moderately conserved among mammals

Summary

GABRF encodes the theta subunit of GABA-A receptors, a rare but pharmacologically distinct isoform with unique expression patterns in the human brain. While less abundant than other GABA-A receptor subunits, theta-containing receptors play important roles in specific neural circuits involved in memory, olfaction, and neuroendocrine regulation. Changes in GABRF expression and function are implicated in Alzheimer's disease, Parkinson's disease, and epilepsy, making it a potentially valuable therapeutic target. The restricted expression pattern offers opportunities for selective drug development with reduced side effects compared to broadly acting GABAergic agents.

Further research is needed to fully understand theta subunit function and to develop selective pharmacological tools. However, the unique properties of theta-containing GABA-A receptors make them an promising avenue for treating neurodegenerative and neurological disorders.

References

[Whittaker MT et al., GABA-A receptor theta subunit: a distinct isoform, Neurochem Res (2010)](https://pubmed.ncbi.nlm.nih.gov/20665477/)

[Browne SH et al., GABA-A receptor heterogeneity: functional implications, J Neurosci (2015)](https://pubmed.ncbi.nlm.nih.gov/25855173/)

[抓到你了 M et al., The theta subunit: structure and function, Pharmacol Rev (2018)](https://pubmed.ncbi.nlm.nih.gov/30540255/)

[Sur C et al., Regional expression of GABA-A receptor theta subunits, Brain Res (2018)](https://pubmed.ncbi.nlm.nih.gov/29754657/)

[Lakhani K et al., Theta-containing GABA-A receptors in memory, Hippocampus (2019)](https://pubmed.ncbi.nlm.nih.gov/31094328/)

[Petrou D et al., GABAergic signaling in Alzheimer's disease, Neurobiol Aging (2020)](https://pubmed.ncbi.nlm.nih.gov/32044182/)

[Zhang L et al., Targeting GABA-A receptors for neurodegeneration, Nat Rev Drug Discov (2021)](https://pubmed.ncbi.nlm.nih.gov/34088902/)

[Friedman A et al., GABA-A receptor subunit composition in aging, J Gerontol A (2022)](https://pubmed.ncbi.nlm.nih.gov/35084623/)

[Robello A et al., Novel allosteric modulators of GABA-A receptors, Neuropharmacology (2013)](https://pubmed.ncbi.nlm.nih.gov/23454317/)

[Maurer L et al., Allosteric modulation of GABA-A receptors, Curr Neuropharmacol (2017)](https://pubmed.ncbi.nlm.nih.gov/28482967/)

[Hanlon VM et al., Theta subunit deletion and epilepsy, Ann Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31161623/)

[Olson CO et al., GABAergic dysfunction in Parkinson's disease, Mov Disord (2020)](https://pubmed.ncbi.nlm.nih.gov/32608134/)

[Yang X et al., Selective neuronal vulnerability in GABAergic disorders, Prog Neuropsychopharmacol (2021)](https://pubmed.ncbi.nlm.nih.gov/33957289/)

[Koh MT et al., GABAergic interventions for cognitive decline, Transl Psychiatry (2022)](https://pubmed.ncbi.nlm.nih.gov/35292456/)

[Rissman RA, Mobley WC, GABAergic target for neurodegenerative disease, Neurodegener Dis (2013)](https://pubmed.ncbi.nlm.nih.gov/23411098/)

📖 View canonical wiki page →

Related Entities

GABRF

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-gabrf
kg_node_id	GABRF
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ba417b7b33d4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-gabrf'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

5%

Debates

0

Incoming

1

Outgoing

3

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

Overview

Gene and Protein Structure

Genomic Organization

Protein Domain Architecture

Distinct Structural Features

Receptor Assembly and Stoichiometry

Native Receptor Composition

Regional Expression Patterns

Physiological Functions

Synaptic Inhibition

Memory and Cognition

Neuroendocrine Regulation

Role in Neurological Disorders

Alzheimer's Disease

Parkinson's Disease

Epilepsy

Therapeutic Implications

Drug Development Targets

Challenges and Opportunities

Comparative Pharmacology

Aging and Neurodegeneration

Neurodegenerative Vulnerability

Interventional Strategies

Genetic Variants and Polymorphisms

Disease-Associated Variants

Population Genetics

Summary

See Also

References

💬 Discussion

📗 Cite This Artifact

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

GABRF Gene — Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

Overview

Gene and Protein Structure

Genomic Organization

Protein Domain Architecture

Distinct Structural Features

Receptor Assembly and Stoichiometry

Native Receptor Composition

Regional Expression Patterns

Physiological Functions

Synaptic Inhibition

Memory and Cognition

Neuroendocrine Regulation

Role in Neurological Disorders

Alzheimer's Disease

Parkinson's Disease

Epilepsy

Therapeutic Implications

Drug Development Targets

Challenges and Opportunities

Comparative Pharmacology

Aging and Neurodegeneration

Age-Related Changes

Neurodegenerative Vulnerability

Interventional Strategies

Genetic Variants and Polymorphisms

Disease-Associated Variants

Population Genetics

Summary

See Also

References

💬 Discussion